肥胖背后的分子机制及其在当前和未来治疗中的潜在利用
Michał Nicze1, Adrianna Dec1, Maciej Borówka1
1Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
International journal of molecular sciences
|August 10, 2024
概括
肥胖是一种慢性疾病,影响生活质量,增加糖尿病和心脏病的风险. 本综述探讨了针对这些途径的分子机制和抗肥胖药物.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一种复杂的慢性疾病,由热量失衡引起,显著增加2型糖尿病和心血管疾病的风险.
- 它会对生活质量产生负面影响,并减少预期寿命.
- 了解肥胖的分子基础对于开发有效的治疗策略至关重要.
研究的目的:
- 审查肥胖的分子病理机制.
- 为了确定抗肥胖药物的分子标.
- 讨论当前和新兴的肥胖药理疗法.
主要方法:
- 文献综述,重点关注肥胖的分子机制.
- 分析中枢神经系统,大脑-肠-微生物群轴,胃肠机动性和能量消耗.
- 评估基于隐素的药物 (GLP-1受体激动剂,双GLP-1/GIP受体激动剂) 和新型治疗分子.
主要成果:
- 分子点包括中枢神经系统,大脑-肠-微生物群轴,胃肠机动性和能量消耗.
- GLP-1受体激动剂 (利拉格卢提德,塞马格卢提德) 和提尔泽帕提德在减肥和代谢改善方面表现出显著的有效性.
- 新型候选药物正在临床研究中,用于未来的肥胖管理.
结论:
- 分子途径为抗肥胖药物治疗提供了可行的点.
- 目前基于因克雷的疗法在治疗肥胖及其并发性疾病方面显示出巨大的前景.
- 目前正在进行的新型分子研究表明,肥胖治疗的前景充满希望.
相关概念视频
Obesity
418
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
418
Regulation of Food Intake
208
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
208
Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311
Regulation of Metabolism
9.3K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Overview of Lipid Metabolism
1.2K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.2K


